Published in AIDS Weekly, May 17th, 2004
The coalition's goal is to bring combination therapies to African and Caribbean nations at one-fifth of the lowest cost available in Western markets.
The deal comes as large pharmaceutical companies express concern about the introduction of cheaper, generic therapies produced by Indian and South African companies. Though generics sometimes infringe on U.S. and European patents, they are lauded as an affordable weapon in the fight against HIV/AIDS.
This deal marks the first time...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.